Merck said on Thursday its experimental antibody therapy, clesrovimab, demonstrated a 60.4% effectiveness in reducing some ...

Respiratory Illness season is right around the corner and experts are urging parents to take action to protect their newborns ...

Study explores the clinical manifestations, risk factors, and 90-day mortality outcomes in adults hospitalized with RSV or ...

Detailed data from a Phase 2b/3 study of Merck’s treatment clesrovimab should support the company’s efforts to win approval ...

Merck reported positive results for its experimental treatment designed to protect infants from RSV. The mid to late-stage ...

EDP-323 is an investigational inhibitor of Respiratory Syncytial Virus (RSV), currently showing promising results in Phase 2a ...

Clesrovimab is an extended half-life RSV neutralizing antibody in development for all infants in their first RSV season and ...

A Phase IIb/III trial with infants entering their first respiratory syncytial virus (RSV) season met its primary endpoints.

RSV, or Respiratory Syncytial Virus, is a highly contagious virus that frequently spreads among preschool children, ...

Merck is discussing the study data with regulators worldwide, with a goal of making the treatment available for infants as early as the 2025 to 2026 RSV season.

The Eastern Ontario Health Unit is advising a new treatment is now available in the region to help protect infants from the most-severe effects of respiratory syncytial virus (RSV).

Despite being back in the season of sniffles and sick days, Washington state will be extra equipped to battle the spread of respiratory viruses this year.